Search

everythinglearnresearchcommunity

for

Search:↓

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

Researchers found genes that control hair color and growth change before the visible coat color changes in snowshoe hares.

The research suggests that autophagy-related genes might play a role in causing alopecia areata.

Hair aging and loss are caused by genetics, hormones, environment, and grooming, with treatments like minoxidil effective for certain types of hair loss.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.

A new topical treatment using SAMiRNA technology shows promise in increasing hair growth for androgenetic alopecia.

The study found that aging hair follicle stem cells change behavior, leading to hair loss, but drugs targeting these cells may help restore hair growth.

Certain genes influence immunoglobulin levels in Chinese Holstein cows, which can improve calf health.

NSG mice had the most mites, and genetic factors affect immune response and susceptibility.

The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Overexpressing the mineralocorticoid receptor in mouse skin causes skin thinning, early skin barrier development, eye issues, and hair loss.

Both mouse and rat models are effective for testing alopecia areata treatments.

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

Early diagnosis and treatment are crucial for preventing permanent hair loss in various scalp conditions, and while new treatments are promising, more research is needed to evaluate their effectiveness.

The conclusion is that future hair loss treatments should target the root causes of hair thinning, not just promote hair growth.

Substance from human umbilical cord blood cells promotes hair growth.

Low TRPS1 expression in skin and hair cells is linked to hair problems in Trichorhinophalangeal syndrome.

New treatments for skin conditions related to the sebaceous gland are being developed based on current research.

The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.

Transfollicular drug delivery is promising but needs more research to improve and understand it better.

Human hair-derived particles can effectively carry and release the cancer drug Paclitaxel in a pH-sensitive manner, potentially targeting cancer cells while sparing healthy ones.

Analog 23 is a promising compound for prostate cancer treatment.

Albumin and prednisone improved symptoms in a woman with Cronkhite-Canada syndrome, revealing potential genetic causes.